SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer

Oncotarget

Volumn 7, Issue 32, 2016, Pages 50997-51011

  Bloom, Jordan E ^a   McNeel, Douglas G ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

CTA; EMT; Focal adhesion; Prostate cancer; SSX

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL ADHESION; CELL ANCHORAGE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SSX2 GENE; TISSUE ADHESION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE; TUMOR EMBOLISM; TUMOR INVASION; XENOGRAFT;

REPRESSOR PROTEIN; SYNOVIAL SARCOMA X BREAKPOINT PROTEINS; TUMOR PROTEIN;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS;

EID: 84982306253     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9802     Document Type: Article

References (46)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30.
2. Feldman BJ and Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer. 2001; 1(1):34-45.
3. Barqawi AB, Krughoff KJ and Eid K. Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. Advances in urology. 2012; 2012:862639.
4. Crawford ED, Higano CS, Shore ND, Hussain M and Petrylak DP. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015; 194(6):1537-1547.
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-1197.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005.
7. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-223.
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW and Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-422.
9. Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG and Pfreundschuh M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 1996; 56(20):4766-4772.
10. Scanlan MJ, Simpson AJ and Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004; 4:1.
11. Forrester JV, Xu H, Lambe T and Cornall R. Immune privilege or privileged immunity? Mucosal immunology. 2008; 1(5):372-381.
12. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Molecular oncology. 2011; 5(2):164-182.
13. Dubovsky JA and McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate. 2007; 67(16):1781-1790.
14. Smith HA, Cronk RJ, Lang JM and McNeel DG. Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer. Cancer Res. 2011; 71(21):6785-6795.
15. Lim FL, Soulez M, Koczan D, Thiesen HJ and Knight JC. A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene. 1998; 17(15):2013-2018.
16. de Bruijn DR, dos Santos NR, Kater-Baats E, Thijssen J, van den Berk L, Stap J, Balemans M, Schepens M, Merkx G and van Kessel AG. The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer. 2002; 34(3):285-298.
17. Chen L, Zhou WB, Zhao Y, Liu XA, Ding Q, Zha XM and Wang S. Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERalpha signaling. Int J Oncol. 2012; 40(6):1986-1994.
18. D'Arcy P, Maruwge W, Wolahan B, Ma L and Brodin B. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. PloS one. 2014; 9(4):e95136.
19. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M and Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005; 65(6):2207-2215.
20. Larue L and Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24(50):7443-7454.
21. Smith HA and McNeel DG. The SSX family of cancertestis antigens as target proteins for tumor therapy. Clinical & developmental immunology. 2010; 2010:150591.
22. Gure AO, Wei IJ, Old LJ and Chen YT. The SSX gene family: characterization of 9 complete genes. Int J Cancer. 2002; 101(5):448-453.
23. Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL and Morrissey C. Single cell transcriptomic analysis of prostate cancer cells. BMC molecular biology. 2013; 14:6.
24. Wang Y and McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. The Journal of cell biology. 2012; 196(3):375-385.
25. Bijian K, Lougheed C, Su J, Xu B, Yu H, Wu JH, Riccio K and Alaoui-Jamali MA. Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine. Br J Cancer. 2013; 109(11):2810-2818.
26. Tamura M, Osajima A, Nakayamada S, Anai H, Kabashima N, Kanegae K, Ota T, Tanaka Y and Nakashima Y. High glucose levels inhibit focal adhesion kinase-mediated wound healing of rat peritoneal mesothelial cells. Kidney international. 2003; 63(2):722-731.
27. Pinco KA, He W and Yang JT. alpha4beta1 integrin regulates lamellipodia protrusion via a focal complex/focal adhesion-independent mechanism. Molecular biology of the cell. 2002; 13(9):3203-3217.
28. Verweij J and Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anti-cancer drugs. 1990; 1(1):5-13.
29. Colleoni GW, Capodieci P, Tickoo S, Cossman J, Filippa DA and Ladanyi M. Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma. Human pathology. 2002; 33(5):496-502.
30. Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, Belch AR and Pilarski LM. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother. 2005; 28(6):564-575.
31. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, Tsang S, Seitz G, Old LJ and Pfreundschuh M. Expression of SSX genes in human tumors. Int J Cancer. 1998; 77(1):19-23.
32. Li RX, Chen ZH and Chen ZK. The role of EPH receptors in cancer-related epithelial-mesenchymal transition. Chinese journal of cancer. 2014; 33(5):231-240.
33. Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, Chen J, Wang J and Chen Z. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol. 2012; 29(4):2691-2700.
34. Yuan W, Chen Z, Wu S, Ge J, Chang S, Wang X, Chen J and Chen Z. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathology oncology research: POR. 2009; 15(3):473-478.
35. Liu C, Huang H, Wang C, Kong Y and Zhang H. Involvement of ephrin receptor A4 in pancreatic cancer cell motility and invasion. Oncology letters. 2014; 7(6):2165-2169.
36. Maschler S, Gebeshuber CA, Wiedemann EM, Alacakaptan M, Schreiber M, Custic I and Beug H. Annexin A1 attenuates EMT and metastatic potential in breast cancer. EMBO molecular medicine. 2010; 2(10):401-414.
37. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, Pardali E, Le Devedec SE, Smit VT, van der Wal A, Van't Veer LJ, Cleton-Jansen AM, ten Dijke P and van de Water B. Annexin A1 regulates TGFbeta signaling and promotes metastasis formation of basallike breast cancer cells. Proc Natl Acad Sci U S A. 2010; 107(14):6340-6345.
38. Soulez M, Saurin AJ, Freemont PS and Knight JC. SSX and the synovial-sarcoma-specific chimaeric protein SYTSSX co-localize with the human Polycomb group complex. Oncogene. 1999; 18(17):2739-2746.
39. Tan MH, Li J, Xu HE, Melcher K and Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta pharmacologica Sinica. 2015; 36(1):3-23.
40. Chang SS. Overview of prostate-specific membrane antigen. Reviews in urology. 2004; 6 Suppl 10:S13-18.
41. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol. 2001; 12 Suppl 2:S141-144.
42. Parimi V, Goyal R, Poropatich K and Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. American journal of clinical and experimental urology. 2014; 2(4):273-285.
43. Smith HA and McNeel DG. Vaccines targeting the cancertestis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother. 2011; 34(8):569-580.
44. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45.
45. Edgar R, Domrachev M and Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30(1):207-210.
46. Mohanty S and Xu L. Experimental metastasis assay. Journal of visualized experiments: JoVE. 2010; (42).